Literature DB >> 16128679

Biliary secretion of moxifloxacin in obstructive cholangitis and the non-obstructed biliary tract.

D Schwab1, M Grauer, E G Hahn, S Mühldorfer.   

Abstract

BACKGROUND: Biliary secretion of antibiotic agents into the bile is considerably compromised by biliary obstruction, a precondition of bacterial cholangitis. Moxifloxacin may be advantageous according to secretion and antimicrobial spectrum. AIM: To establish the secretion of moxifloxacin into obstructed and non-obstructed bile.
METHODS: Biliary excretion of moxifloxacin was determined in plasma and bile of 10 patients with biliary obstruction and cholangitis and 10 patients without biliary obstruction 30 min after administration of 400 mg of moxifloxacin intravenously.
RESULTS: The plasma concentration of moxifloxacin was similar in both groups (4.45 +/- 1.58 microg/mL; 4.33 +/- 1.23 microg/mL). The concentration of moxifloxacin in the bile was significantly lower in patients with biliary obstruction than without (4.63 +/- 3.94 microg/mL; range 0.71-14.40; vs. 16.90 +/- 13.77 microg/mL; range 1.79-42.50; P = 0.043). Although significantly different, the penetration index was extensively high in those without biliary obstruction (4.41 +/- 4.40; range 0.35-14.45) but still sufficient in those patients with obstructive cholangitis (1.02 +/- 0.74; range 0.29-2.83; P = 0.035).
CONCLUSION: These findings are suggestive of an active secretion mechanism for moxifloxacin into the obstructed bile, producing a biliary concentration sufficiently above the minimal inhibitory concentrations for most of the expected bacteria.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16128679     DOI: 10.1111/j.1365-2036.2005.02567.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

1.  Lack of ethnic differences of moxifloxacin and metabolite pharmacokinetics in East Asian men.

Authors:  M Kaneko; T Aoyama; Y Ishida; A Miyamoto; Y Saito; M Tohkin; S Kawai; Y Matsumoto
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-11-23       Impact factor: 2.745

2.  Acute bacterial cholangitis.

Authors:  Mamta K Jain; Rajeev Jain
Journal:  Curr Treat Options Gastroenterol       Date:  2006-04

Review 3.  BDDCS, the Rule of 5 and drugability.

Authors:  Leslie Z Benet; Chelsea M Hosey; Oleg Ursu; Tudor I Oprea
Journal:  Adv Drug Deliv Rev       Date:  2016-05-13       Impact factor: 15.470

4.  In vitro activity of moxifloxacin and piperacillin/sulbactam against pathogens of acute cholangitis.

Authors:  Andreas Weber; Wolfgang Huber; Klaus Kamereck; Philipp Winkle; Petra Voland; Hans Weidenbach; Roland M Schmid; Christian Prinz
Journal:  World J Gastroenterol       Date:  2008-05-28       Impact factor: 5.742

Review 5.  Gender analysis of moxifloxacin clinical trials.

Authors:  Elisa Chilet-Rosell; Ma Teresa Ruiz-Cantero; Ma Angeles Pardo
Journal:  J Womens Health (Larchmt)       Date:  2013-11-01       Impact factor: 2.681

6.  Acute cholecystitis - early laparoskopic surgery versus antibiotic therapy and delayed elective cholecystectomy: ACDC-study.

Authors:  Kilian Weigand; Jörg Köninger; Jens Encke; Markus W Büchler; Wolfgang Stremmel; Carsten N Gutt
Journal:  Trials       Date:  2007-10-04       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.